Cover Image

The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors

Abstract Background Immune checkpoint inhibitors (ICIs) have witnessed the achievements of convincing clinical benefits that feature the significantly prolonged overall survival (OS) of patients suffering from advanced non-small cell lung cancer (NSCLC), according to reports recently. Sensitivity to...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xilin Hu (Author), Hanlin Xu (Author), Qianwen Xue (Author), Ruran Wen (Author), Wenjie Jiao (Author), Kaihua Tian (Author)
Format:	Book
Published:	BMC, 2021-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors
by: Yuchun Niu, et al.
Published: (2020)

GBP5 Expression Predicted Prognosis of Immune Checkpoint Inhibitors in Small Cell Lung Cancer and Correlated with Tumor Immune Microenvironment
by: Tong Q, et al.
Published: (2023)

First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress
by: Zhangfeng Huang, et al.
Published: (2020)

B Cell Receptor Signaling Pathway Mutation as Prognosis Predictor of Immune Checkpoint Inhibitors in Lung Adenocarcinoma by Bioinformatic Analysis
by: Lin A, et al.
Published: (2022)

Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer
by: Dantong Sun, et al.
Published: (2020)

Mutations Status of Chemokine Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colon Adenocarcinoma
by: Anqi Lin, et al.
Published: (2021)

Mutations Status of NOTCH Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colorectal Cancer
by: Lin A, et al.
Published: (2023)

Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung Cancer
by: Ivy Riano, et al.
Published: (2023)

The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients' age
by: Yongfeng Wu, et al.
Published: (2020)

Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors
by: Yang Wen, et al.
Published: (2021)

Predictive biomarkers for immune checkpoint inhibitors therapy in lung cancer
by: Jie Yao, et al.
Published: (2024)

Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors
by: Xue-lin Zou, et al.
Published: (2021)

Obesity paradox in patients with non‐small cell lung cancer undergoing immune checkpoint inhibitor therapy
by: Ji Hyun Lee, et al.
Published: (2023)

Predictive markers of response to immune checkpoint inhibitor rechallenge in metastatic non-small cell lung cancer
by: Aram A. Musaelyan, et al.
Published: (2024)

Risk Factors and Prognostic Analysis of Immune Checkpoint Inhibitor-Related Colitis in Lung Cancer
by: Wang S, et al.
Published: (2024)

MGA Mutation as a Novel Biomarker for Immune Checkpoint Therapies in Non-Squamous Non-Small Cell Lung Cancer
by: Lei Sun, et al.
Published: (2021)

Exploring histological predictive biomarkers for immune checkpoint inhibitor therapy response in non-small cell lung cancer
by: Uiju Cho, et al.
Published: (2024)

Prognostic value of lung immune prognostic index in non-small cell lung cancer patients receiving immune checkpoint inhibitors: a meta-analysis
by: Yi Wang, et al.
Published: (2024)

Neutrophil-related genes predict prognosis and response to immune checkpoint inhibitors in bladder cancer
by: Rui Yang, et al.
Published: (2022)

Emerging trends and focus on immune checkpoint inhibitors for non-small cell lung cancer treatment: visualization and bibliometric analysis
by: Yue Zhang, et al.
Published: (2023)

Potential non-invasive biomarkers in tumor immune checkpoint inhibitor therapy: response and prognosis prediction
by: Ruixia Song, et al.
Published: (2023)

Effects of combining immune checkpoint inhibitors and anti-angiogenic agents on bone metastasis in non-small cell lung cancer patients
by: Xiaohong Xie, et al.
Published: (2023)

Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis
by: Yu Lu, et al.
Published: (2023)

It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC
by: Ken Akao, et al.
Published: (2024)

Acute Kidney Injury Induced by Immune Checkpoint Inhibitors
by: Ruixue Tian, et al.
Published: (2022)

Immune Checkpoint Inhibitors New Insights and Recent Progress
Published: (2023)

Immune Checkpoint Inhibitor-Associated Systemic Sclerosis in the Treatment of a Small Cell Lung Cancer Patient with Durvalumab: A Case Report
by: Li DH, et al.
Published: (2024)

An application of ERBB2 receptor inhibitors in a rare case of S310F somatic ERBB2 mutation of primary signet-ring cell adenocarcinoma of vagina: A case report and review literature of S310F somatic ERBB2 mutation in breast and gynecologic cancers
by: June Y. Hou, et al.
Published: (2020)

The gut microbiota and immune checkpoint inhibitors
by: Audrey Humphries, et al.
Published: (2018)

Cardiovascular complications of immune checkpoint inhibitors
by: A. A. Kulievа, et al.
Published: (2020)

Immune Checkpoint Inhibitors and Lupus Erythematosus
by: Hans Vitzthum von Eckstaedt, et al.
Published: (2024)

Inactivating mutations in genes encoding for components of the BAF/PBAF complex and immune-checkpoint inhibitor outcome
by: Kevin Courtet, et al.
Published: (2020)

Association of clock-like mutational signature with immune checkpoint inhibitor outcome in patients with melanoma and NSCLC
by: Wei Chong, et al.
Published: (2021)

Survival Prediction of Patients Treated With Immune Checkpoint Inhibitors via KRAS/TP53/EGFR-Single Gene Mutation
by: Shui Liu, et al.
Published: (2022)

An analysis report on the application of immune checkpoint inhibitors after liver transplantation
by: Man Xie, et al.
Published: (2022)

Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis
by: Zijing Liu, et al.
Published: (2023)

The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review
by: Qing-Qing Chai, et al.
Published: (2019)

Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis of Randomized Clinical Trials
by: Weidong Zhang, et al.
Published: (2021)

Risk and safety profile in checkpoint inhibitors on non-small-cell lung cancer: A systematic review
by: Sara Maria Majernikova
Published: (2024)

Skin Manifestation Induced by Immune Checkpoint Inhibitors
by: Yamamoto T
Published: (2022)